 | SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMs)
Copyright © 2001 by the New York Academy of Sciences
description
Annals of the New York Academy of Sciences 949:243-250 (2001)
© 2001 New York Academy of Sciences
Effect of Selective Estrogen Receptor Modulators on Reproductive Tissues Other Than Endometrium
SUSAN L. HENDRIX AND
S. GENE McNEELEY
Department of Obstetrics and Gynecology, Wayne State University/Hutzel Hospital, Detroit, Michigan 48201, USA
Address for correspondence: Susan L. Hendrix, D.O. Department of Obstetrics and Gynecology, Wayne State University/Hutzel Hospital, 4707 St. Antoine, Detroit, MI 48201. Voice: 313-966-910; fax: 313-993-8504.
shendrix{at}med.wayne.edu
The objective of this paper is to review the published and unpublished knowledge of the effect of selective estrogen receptor modulators on reproductive tissues other than endometrium. Pharmaceutical companies developing or marketing selective estrogen receptor modulators (SERMs) were identified. The investigators at each company responsible for the conduct of investigational trials were contacted and queried about reports of adverse events in any ongoing or completed trials involving SERMs produced by their company. Levormeloxifene and idoxifene trials noted a higher proportion of surgery for pelvic organ prolapse in treated versus untreated women. The development of these pharmaceutical agents was discontinued, primarily for endometrial concerns. However, pelvic organ prolapse was reported to the FDA as an adverse event associated with both drugs. Study weaknesses preclude a definitive association between the agents and pelvic organ prolapse. The treated groups were not necessarily similar for confounding factors such as age, parity, obesity, cigarette smoking, and other risk factors for pelvic organ prolapse. Tamoxifen and raloxifene increase hot flash intensity and frequency. Ovarian cyst formation and uterine fibroid growth have also been reported with some SERMs. The identification and assessment of the impact of current and future SERMs on the pelvic floor and other genital tissues will be important to understanding their potential long-term application in disease treatment and prevention.
Key Words: selective estrogen receptor modulators • pelvic organ prolapse • hot flashes • vagina • ovary • fallopian tube • myometrium • tamoxifen • raloxifene • idoxifene
This article has been cited by other articles:
|
|
|
|
 
A. A.A. Ewies, M. Elshafie, J. Li, A. Stanley, J. Thompson, J. Styles, I. White, and F. Al-Azzawi
Changes in transcription profile and cytoskeleton morphology in pelvic ligament fibroblasts in response to stretch: the effects of estradiol and levormeloxifene
Mol. Hum. Reprod.,
February 1, 2008;
14(2):
127 - 135.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. E. Waetjen, J. S. Brown, E. Vittinghoff, K. E. Ensrud, J. Pinkerton, R. Wallace, J. L. Macer, D. Grady, and for the Ultra Low Dose Transdermal estRogen Assess
The Effect of Ultralow-Dose Transdermal Estradiol on Urinary Incontinence in Postmenopausal Women
Obstet. Gynecol.,
November 1, 2005;
106(5):
946 - 952.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. S. Komm, Y. P. Kharode, P. V. N. Bodine, H. A. Harris, C. P. Miller, and C. R. Lyttle
Bazedoxifene Acetate: A Selective Estrogen Receptor Modulator with Improved Selectivity
Endocrinology,
September 1, 2005;
146(9):
3999 - 4008.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. A.A. Ewies, J. Thompson, and F. Al-Azzawi
Changes in gonadal steroid receptors in the cardinal ligaments of prolapsed uteri: immunohistomorphometric data
Hum. Reprod.,
July 1, 2004;
19(7):
1622 - 1628.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. D. Slayden, K. Hettrich, R. S. Carroll, L. N. Otto, A. L. Clark, and R. M. Brenner
Estrogen Enhances Cystatin C Expression in the Macaque Vagina
J. Clin. Endocrinol. Metab.,
February 1, 2004;
89(2):
883 - 891.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. A. Martin, K. Brown, M. Gaskell, F. Al-Azzawi, R. C. Garner, D. J. Boocock, E. Mattock, D. W. Pring, K. Dingley, K. W. Turteltaub, et al.
Tamoxifen DNA Damage Detected in Human Endometrium Using Accelerator Mass Spectrometry
Cancer Res.,
December 1, 2003;
63(23):
8461 - 8465.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
